Amprenavir
From Wikipedia, the free encyclopedia
Amprenavir
|
|
Systematic (IUPAC) name | |
tetrahydrofuran-3-yl [3-[(4-aminophenyl)sulfonyl- (2-methylpropyl) amino] -1-benzyl-2- hydroxy-propyl] aminomethanoate | |
Identifiers | |
CAS number | 161814-49-9 |
ATC code | J05AE05 |
PubChem | 65016 |
DrugBank | APRD00605 |
Chemical data | |
Formula | C25H35N3O6S |
Mol. weight | 505.628 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 90% |
Metabolism | ? |
Half life | 7.1-10.6 hours |
Excretion | ? |
Therapeutic considerations | |
Licence data | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Amprenavir (Agenerase®) is a protease inhibitor used to treat HIV. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200mg, delivered in eight very large gel capsules. Production of amprenavir was discontinued by the manufacturer December 31, 2004.
Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|